Biocompatible riboflavin laurate long-acting injectable nanosuspensions allowing sterile filtration

Drug Delivery

Volumn 21, Issue 5, 2014, Pages 351-361

  Hu, Xi ^a   Lin, Xia ^a   Gu, Yuechen ^a   Liu, Zitong ^a   Tang, Yilin ^b   Zhang, Yu ^a   Chen, Xi ^a   Wang, Yanjiao ^a   Tang, Xing ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Long acting injectable nanosuspensions; Low irritation; Precipitation combined high pressure homogenization; Riboflavin laurate; Sterile filtration

Indexed keywords

LONG ACTING DRUG; NANOSPHERE; PHOSPHATIDYLCHOLINE; POLYSORBATE 80; POVIDONE DERIVATIVE; RIBOFLAVIN DERIVATIVE; RIBOFLAVIN LAURATE; STABILIZING AGENT; TOCOFERSOLAN; UNCLASSIFIED DRUG; BIOMATERIAL; EXCIPIENT; LAURIC ACID DERIVATIVE; NANOPARTICLE; POWDER; RIBOFLAVIN; SUSPENSION;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STERILITY; ENTROPY; FEMALE; FILTRATION; HYDROPHOBICITY; HYPERBARISM; INFLAMMATION; INFRARED SPECTROSCOPY; INJECTION; MALE; MEMBRANE FILTER; NANOSUSPENSION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRECIPITATION; PRIORITY JOURNAL; RAT; SKIN IRRITATION; TRANSMISSION ELECTRON MICROSCOPY; X RAY POWDER DIFFRACTION; ADMINISTRATION AND DOSAGE; ANIMAL; CHEMISTRY; DRUG STABILITY; MEDICINAL CHEMISTRY; POWDER; PROCEDURES; SCANNING ELECTRON MICROSCOPY; SOLUBILITY; SUSPENSION; X RAY DIFFRACTION;

ANIMALS; BIOCOMPATIBLE MATERIALS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DRUG STABILITY; EXCIPIENTS; LAURATES; MALE; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PARTICLE SIZE; POWDERS; RATS; RIBOFLAVIN; SOLUBILITY; SUSPENSIONS; X-RAY DIFFRACTION;

EID: 84903217335     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2013.850760     Document Type: Article

References (25)

1. Cai T, Jiang Y, Tian S. (2005). Determination of residual solvent N,Ndimethylformamide in aripiprazole by headspace gas chromatography. Chin J New Drugs 14:327-9.
2. Cheppudira BP. (2006). Characterization of hind paw licking and lifting to noxious radiant heat in the rat with and without chronic inflammation. J Neurosci Methods 155:122-5. (Pubitemid 43849993)
3. D'addio SM, Prud'homme RK. (2011). Controlling drug nanoparticle formation by rapid precipitation. Adv Drug Deliv Rev, 63, 417-26.
4. Du L, Li G, Jin Y, et al. (2013). Riboflavin laurate nanosuspensions as an intramuscular injection for long-term riboflavin supplementation. Int J Pharm 450:338-44.
5. Celozzi E, Lotti VJ, Stapley EO, Miller AK. (1980). An animal model for assessing pain-on-injection of antibiotics. J Pharmacol Methods 4: 285-9. (Pubitemid 11125772)
6. FDA (2011). Available from: http://www.accessdata.fda.gov/scripts/cder/ dissolution/dsp-SearchResults-Dissolutions.cfm [last accessed 9 Jan 2011].
7. Franois MKJ, Dries WMAC, Basstanie EDG (2003). Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters. US patent no. US 6555544.
8. Ghosh I, Bose S, Vippagunta R, Harmon F. (2011). Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth. Int J Pharm 409:260-8.
9. Goldsmith G. (1975). Riboflavin deficiency. In: Rivlin R, ed. Riboflavin. US: Springer, 221-44.
10. Italia JL, Bhatt DK, Bhardwaj V, et al. (2007). PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral. J Control Release 119: 197-206. (Pubitemid 46778760)
11. Keck CM, Muller RH. (2006). Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 62:3-16. (Pubitemid 41736019)
12. Kipp JE, Wong JCT, Doty MJ, Rebbeck CL. (2003). Microprecipitation method for preparing submicron suspensions. US patent no. US 6607784.
13. Porrini M, Simonetti P, Testolin G, et al. (1991). Relation between diet composition and coronary. J Epidemiol Community Health 45: 148-51.
14. Mohanty C, Sahoo SK. (2010). The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials 31:6597-611.
15. Mulik RS, Monkkonen J, Juvonen RO, et al. (2010). Transferrin mediated solid lipid nanoparticles containing curcumin: enhanced in vitro anticancer activity by induction of apoptosis. Int J Pharm 398: 190-203.
16. Yallapu MM, Dobberpuhl MR, Maher DM, et al. (2012). Design of curcumin loaded cellulose nanoparticles for prostate cancer. Curr Drug Metab 13:120-8.
17. Muño N, Crespi M, Grassi A, et al. (1982). Precursor lesions of oesophageal cancer in high-risk populations in Iran and China. The Lancet 319:876-9. (Pubitemid 12140279)
18. Nasrallah HA, Gopal S, Gassmann-Mayer C, et al. (2010). A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology 35: 2072-82.
19. Rabinow BE. (2004). Nanosuspensions in drug delivery. Nat Rev Drug Discov 3:785-96. (Pubitemid 39242830)
20. Sovizi MR, Hajimirsadeghi SS, Naderizadeh B. (2009). Effect of particle size on thermal decomposition of nitrocellulose. J Hazard Mater 168: 1134-9.
21. Tobyn M, Brown J, Dennis AB, et al. (2009). Amorphous drug-PVP dispersions: application of theoretical, thermal and spectroscopic analytical techniques to the study of a molecule with intermolecular bonds in both the crystalline and pure amorphous state. J Pharm Sci 98:3456-68.
22. Venkatesh T, Reddy AK, Maheswari JU, et al. (2011). Nanosuspensions: ideal approach for the drug delivery of poorly water soluble drugs. Der Pharmacia Lettre 3:203-13.
23. Wu L, Zhang J, Watanabe W. (2011). Physical and chemical stability of drug nanoparticles. Adv Drug Deliv Rev 63:456-69.
24. Xu Q, Wang L, Tong C, et al. (2004). A riboflavin derivative and its manufacture and uses. WO patent no. WO/2004/013142.
25. Zhao YX, Hua HY, Chang M, et al. (2010). Preparation and cytotoxic activity of hydroxycamptothecin nanosuspensions. Int J Pharm 392: 64-71.